{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:20:49Z","timestamp":1786735249388,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd007287.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000}}],"reference-count":157,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007287.pub3","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T14:58:06Z","timestamp":1410965886000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antigen-specific active immunotherapy for ovarian cancer"],"prefix":"10.1002","author":[{"given":"Ninke","family":"Leffers","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen; Obstetrics & Gynecology CB30; Hanzeplein 1 P.O. Box 30.001 Groningen Netherlands 9700 RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toos","family":"Daemen","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen; Hanzeplein 1 P.O.Box 30.001 Groningen Netherlands 9700 RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen; Department of Surgery. Translational Surgical Oncology; Hanzeplein 1\/BA44 Groningen Netherlands 9713 GZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Marike","family":"Boezen","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen; Unit Chronic Airway Diseases, Department of Epidemiology; Triade gebouw, E3.29 P.O.Box 30.001 Groningen Netherlands 9700 RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J","family":"Cohlen","sequence":"additional","affiliation":[{"name":"Isala Clinics, Location Sophia; Department of Obstetrics & Gynaecology; Dr van Heesweg 2 P O Box 10400 Zwolle Netherlands 3515 BE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis JM","family":"Melief","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center; Department of Immunohaematology and Blood Transfusion; PO Box 9600 E3-Q Leiden Netherlands 2300 RC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W","family":"Nijman","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen; Hanzeplein 1 P.O.Box 30.001 Groningen Netherlands 9700 RB"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"10.1002\/14651858.CD007287.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2011.06.004","article-title":"Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO study group","volume":"123","author":"Baumann","year":"2011","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0002|cit2","unstructured":"Berek JS Ehlen TG Gordon A Nicodemus CF Schultes B Whiteside TL Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer American Society of Clinical Oncology Annual Meeting 2001"},{"issue":"17","key":"10.1002\/14651858.CD007287.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e31816060ce","article-title":"CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer","volume":"31","author":"Berek","year":"2008","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Berek J Taylor PT McGuire WP Smith LM Schultes B Nicodemus CF Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA) 2008 ASCO Annual Meeting Proceedings 2008","DOI":"10.1200\/jco.2008.26.15_suppl.5507"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer","volume":"10","author":"Berinstein","year":"2012","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Berinstein NL Oza AM Odunsi K Karkada M Villella JA Nemunaitis JJ Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: results of a phase I study American Society of Clinical Oncology Annual Meeting 2013","DOI":"10.1200\/jco.2013.31.15_suppl.3030"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Braly P Chu C Collins Y Edwards R Gordon A McGuire W Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC) American Society of Clinical Oncology Annual Meeting 2007","DOI":"10.1200\/jco.2007.25.18_suppl.3024"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e31818b3dad","article-title":"The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo-immunotherapy in advanced ovarian cancer","volume":"32","author":"Braly","year":"2009","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0011|cit11","unstructured":"Method M Gordon A Smith LM Nicodemus CF Oregovomab immune-modulating antibody therapy concurrent tot standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience Society of Gynecologic Oncologists Annual Meeting on Women's Cancer 2006"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer","volume":"31","author":"Chianese-Bullock","year":"2008","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0014|cit14","unstructured":"Chu CS Boyer J Coukos G Rubin SC Morgan MA Bendig DL Autologous dendritic cell (IDD-6) vaccination as consolidation for advanced ovarian cancer Society of Gynecologic Oncologists: Annual Meeting on Women's Cancer 2008"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-1081-8","article-title":"Phase I\/II randomized tiral of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission","volume":"61","author":"Chu","year":"2012","journal-title":"Cancer Immunology Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0016|cit16","unstructured":"Dhodapkar M Zhao B Wang D Lutzky RD Carvajal RD Keohan M A phase I trial of a novel vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205 in combination with toll-like receptor agonists Society for Immunotherapy of Cancer Annual Meeting 2012"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1525-1438.2005.00483.x","article-title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","volume":"15","author":"Ehlen","year":"2005","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0019|cit19","unstructured":"Freedman RS Kudelka AP Verschraegen CF Edwards CL Tomasovic B Kaplan A Therapeutic anti-cancer vaccine: a randomized double blind dose comparison study of sialyl Tn-KLH with Detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC) American Society of Clinical Oncology Annual Meeting 1998"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0020|cit20","unstructured":"Termrungruanglert W Kudelka AP Verschraegen CF Freedman RS Edwards CL Tomasovic B Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN-K with detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC) American Society of Clinical Oncology Annual Meeting 1996"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Goh J CAN-003 Study Team Gargosky SE Gray H Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission European Cancer Congress 2013","DOI":"10.1186\/2051-1426-1-S1-P213"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2004.04.024","article-title":"CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients","volume":"94","author":"Gordon","year":"2004","journal-title":"Gynecologic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1158\/1078-0432.CCR-04-2111","article-title":"Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy","volume":"11","author":"Gribben","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Imhoff M Lipovac M Angleitner-Boubenizek L Barta J Gomez I Hrdina A Double-loaded mature dendritic cell (DC) therapy for non-HLA-restricted patients with advanced ovarian cancer: final results of a clincal phase I study American Society of Clinical Oncolocy Annual Meeting 2013","DOI":"10.1200\/jco.2013.31.15_suppl.3052"},{"issue":"31","key":"10.1002\/14651858.CD007287.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1200\/JCO.2009.22.3883","article-title":"Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and\/or recurrent solid tumors","volume":"27","author":"Kaumaya","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressin mesothelin (CRS-207) for advanced cancers: pahse I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0030|cit30","first-page":"[Epub ahead of","article-title":"Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial","volume":"May 28","author":"Leffers","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.25980","article-title":"Long-term clinical and immunological effects of p53-SLP vaccine in patients with ovarian cancer","volume":"130","author":"Leffers","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"suppl 6","key":"10.1002\/14651858.CD007287.pub3-BIB0032|cit32","first-page":"194","article-title":"Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy","volume":"34","author":"Letsch","year":"2011","journal-title":"Onkologie"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1349-7006.2002.tb01203.x","article-title":"Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response","volume":"93","author":"Ma","year":"2002","journal-title":"Japanese Journal of Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00002371-199205000-00008","article-title":"Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen","volume":"11","author":"MacLean","year":"1992","journal-title":"Journal of Immunotherapy"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002371-199601000-00007","article-title":"Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine","volume":"19","author":"MacLean","year":"1996","journal-title":"Journal of Immunotherapy With Emphasis on Tumor Immunology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0036|cit36","unstructured":"Method M Gordon A Finkler N Fingert H Nicodemus CF Whiteside TL Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC) American Society of Clinical Oncology Annual Meeting 2002"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mob.2003.347","article-title":"Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer","volume":"189","author":"Mobus","year":"2003","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0038|cit38","unstructured":"Mohebtash M Madan R Tsang K Arlen Ph Pazdur M Jones J Clinical outcomes following immunotherapy with a MUC1\/CEA vaccine in patients with metastatic breast and ovarian cancer American Association of Cancer Research Annual Meeting 2009"},{"issue":"22","key":"10.1002\/14651858.CD007287.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1158\/1078-0432.CCR-11-0649","article-title":"A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer","volume":"17","author":"Mohebtash","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-10-2614","article-title":"MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell repsonses against breast and ovarian cancer","volume":"17","author":"Morse","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00262-004-0522-z","article-title":"A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer","volume":"53","author":"Nicholson","year":"2004","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.4049\/jimmunol.176.10.6340","article-title":"Influence of CD4(+)CD25(+) regulatory T cells on low\/high-avidity CD4(+) T cells following peptide vaccination","volume":"176","author":"Nishikawa","year":"2006","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/10849780152389384","article-title":"Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo","volume":"16","author":"Noujaim","year":"2001","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"issue":"31","key":"10.1002\/14651858.CD007287.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15","key":"10.1002\/14651858.CD007287.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"PNAS"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0046|cit46","unstructured":"Odunsi K Rodabaugh K Lele S Old LJ Matsuzaki J Qian F Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer Society of Gynecologic Oncologists Annual Meeting on Women's Cancer 2007"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0047|cit47","first-page":"2441","article-title":"WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report","volume":"31","author":"Dohi","year":"2001","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0048|cit48","first-page":"4779","article-title":"Wilms'tumor 1 (WT1) peptide immunotherapy for gynecological malignancy","volume":"29","author":"Ohno","year":"2009","journal-title":"Anticancer Research"},{"issue":"18","key":"10.1002\/14651858.CD007287.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-08-3282","article-title":"A phase I trial of immunotherapy with Lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express Her-2\/neu","volume":"15","author":"Peethambaram","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/annonc\/mdl357","article-title":"The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR","volume":"17","author":"Pfisterer","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Herrin V Achtar M Steinberg S Whiteside TL Wieckowsk E Czystowska M A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients American Society of Clinical Oncology Annual Meeting 2007","DOI":"10.1200\/jco.2007.25.18_suppl.3011"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0052|cit52","unstructured":"Herrin V Behrens RJ Achtar M Monahan B Bernstein S Brent-Steele T Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom American Society of Clinical Oncology Annual Meeting 2003"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00262-011-1100-9","article-title":"A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients","volume":"61","author":"Rahma","year":"2012","journal-title":"Cancer Immunology Immunotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-03-0056","article-title":"Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib\/II)","volume":"10","author":"Reinartz","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0055|cit55","first-page":"1154","article-title":"Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment","volume":"7","author":"Wagner","year":"2001","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0056|cit56","first-page":"79","article-title":"Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial","volume":"87","author":"Sabbatini","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"18","key":"10.1002\/14651858.CD007287.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-05-2670","article-title":"Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"12","author":"Sabbatini","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"23","key":"10.1002\/14651858.CD007287.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO - the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00002371-199901000-00008","article-title":"Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine","volume":"22","author":"Sandmaier","year":"1999","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0062|cit62","unstructured":"Schultes B Yang R Agopsowicz K Kuzma M Dharampaul S Baum R Anti-idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex-Mab-B43.13 American Society of Clinical Oncology Annual Meeting 1999"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002620050479","article-title":"Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)","volume":"46","author":"Schultes","year":"1998","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-9966-28-18","article-title":"Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis","volume":"28","author":"Str\u00f6hlein","year":"2009","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Takeuchi S Shoji T Kagabu M Honda T Miura F Omi H A phase I\/II study of multiple peptides cocktail vaccine for advanced\/recurrent ovarian cancer American Society of Clinical Oncology Annual Meeting 2013","DOI":"10.1200\/jco.2013.31.15_suppl.tps3116"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002371-200401000-00006","article-title":"Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers","volume":"27","author":"Tsuda","year":"2004","journal-title":"Journal of Immunotherapy"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00432-002-0348-z","article-title":"Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study","volume":"128","author":"Zanten-Przybysz","year":"2002","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"E670","DOI":"10.1002\/ijc.27388","article-title":"Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study","volume":"131","author":"Vermeij","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0070|cit69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/hyb.1993.12.521","article-title":"Antitumor antibodies for immunotherapy of ovarian carcinomas","volume":"12","author":"Wagner","year":"1993","journal-title":"Hybridoma"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0069|cit70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02789234","article-title":"Monoclonal antibodies and idiotypic network activation for ovarian carcinoma","volume":"24-25","author":"Wagner","year":"1994","journal-title":"Cell Biophysics"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s002620000143","article-title":"Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides","volume":"49","author":"Anderson","year":"2000","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0072|cit72","first-page":"16","article-title":"LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer","volume":"7","author":"Bender","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3892\/ol.2011.424","article-title":"Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells","volume":"3","author":"Bernal","year":"2012","journal-title":"Oncology Letters"},{"issue":"22","key":"10.1002\/14651858.CD007287.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carbone","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub3-BIB0075|cit75","first-page":"1289","article-title":"Generation of immunity to the HER-2\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine","volume":"5","author":"Disis","year":"1999","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0076|cit76","first-page":"1347","article-title":"Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2\/neu peptide immunization","volume":"6","author":"Disis","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2002.06.171","article-title":"Generation of T-cell immunity to the HER-2\/neu protein after active immunization with HER-2\/neu peptide-based vaccines","volume":"20","author":"Disis","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V99.8.2845","article-title":"Flt3 ligand as a vaccine adjuvant in association with HER-2\/neu peptide-based vaccines in patients with HER-2\/neu-overexpressing cancers","volume":"99","author":"Disis","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients","volume":"24","author":"Disis","year":"2004","journal-title":"Journal of Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2004.09.005","article-title":"Effect of dose on immune response in patients vaccinated with an her-2\/neu intracellular domain protein--based vaccine","volume":"22","author":"Disis","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0081|cit81","unstructured":"Galanis E Atherton P Dowdy S Cliby W Haluska P Long H Intraperitoneal (IP) administration of an oncolytic measles virus (MV) strain expressing the sodium iodine symporter gene in patients (pts) with advanced ovarian cancer (ovca) American Society of Gene& Cell Therapy (ASGCT) Annual Meeting 2013"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0082|cit82","unstructured":"Haakenstad H Suso EMI Rasmussen AM Larsen SS Dueland S Lilleby W Clinical use of fast DCs transfected with hTERT and Survivin mRNA - an effective and simplified cancer vaccine approach European Group for Blood and Marrow Transplantation Annual Meeting 2012"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0083|cit83","unstructured":"Kvalheim G Suso E Rasmussen A Honnashagen T Dueland S Gaudernack G Fast DCs transfected with hTERT and Survivin mRNA - a novel, effective and simplified cancer vaccine approach In European Group for Blood and Marrow Transplantation Annual Meeting 2011"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers3022223","article-title":"Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy","volume":"3","author":"Hasumi","year":"2011","journal-title":"Cancers"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-001-0255-1","article-title":"Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial","volume":"51","author":"Hernando","year":"2002","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(07)70142-0","article-title":"Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-(alpha) for relapsed metastatic ovarian cancer","volume":"8","author":"Hernando","year":"2007","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.bmt.1702430","article-title":"Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine","volume":"25","author":"Holmberg","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.gt.3300455","article-title":"Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes","volume":"4","author":"Hui","year":"1997","journal-title":"Gene Therapy"},{"issue":"39","key":"10.1002\/14651858.CD007287.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients","volume":"103","author":"Jager","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0090|cit90","first-page":"s130","article-title":"Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer","volume":"116","author":"Coukos","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub3-BIB0091|cit91","first-page":"878","article-title":"Autologous whole-tumor anitgen combinatorial immunotherapy for recurrent ovarian cancer","volume":"33","author":"Kandalaft","year":"2010","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ijc.24850","article-title":"Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival","volume":"126","author":"Karbach","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub3-BIB0093|cit93","first-page":"2240","article-title":"WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers","volume":"37","author":"Kato","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Khranovska NM Svyntsytsky VS Potebnya GP Vorobyova LI Skachkova Tsyp NP New dendritic cell vaccine therapy approach - randomized phase I\/II study in III-IV stage ovarian cancer patients In: European Multidisciplinary Cancer Conference (ECCO ESMO ESTRO) 2011","DOI":"10.1016\/S0959-8049(11)72127-X"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1172\/JCI11752","article-title":"Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients","volume":"107","author":"Knutson","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0096|cit96","first-page":"1014","article-title":"Immunization of cancer patients with a HER-2\/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity","volume":"8","author":"Knutson","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0097|cit97","unstructured":"Letsch A Asemissen AM Zimmermann K Bauer S Stather D V\u00f6lker-Call M Different quality of T cell repsonses to WT1 peptide vaccination in patients with AML\/MDS and patients with solid tumors Journal of Immunotherapy 2008 943 4"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD007287.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000337319","article-title":"Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report","volume":"5","author":"Manjunath","year":"2012","journal-title":"Case Reports in Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","article-title":"Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas","volume":"23","author":"Marshall","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<62::AID-IJC12>3.0.CO;2-T","article-title":"Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC\/TR in ovarian-carcinoma patients is associated with longer survival","volume":"84","author":"Miotti","year":"1999","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub3-BIB0102|cit102","first-page":"1331","article-title":"A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen","volume":"5","author":"Morse","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.3816\/CBC.2003.s.007","article-title":"Her2 dendritic cell vaccines","volume":"3 suppl. 4","author":"Morse","year":"2003","journal-title":"Clinical Breast Cancer"},{"issue":"14","key":"10.1002\/14651858.CD007287.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-11-0891","article-title":"Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients","volume":"17","author":"Morse","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub3-BIB0105|cit105","first-page":"3407","article-title":"Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer","volume":"8","author":"Murray","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"14","key":"10.1002\/14651858.CD007287.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-04-0325","article-title":"Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase","volume":"10","author":"Parkhurst","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002620050287","article-title":"Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy","volume":"42","author":"Reddish","year":"1996","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Salazar LG Murray JL Disis ML Cheever M A phase I vaccine trial of a HER-2\/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers ASCO Annual Meeting 2006","DOI":"10.1200\/jco.2006.24.18_suppl.2572"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1016009317796","article-title":"Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients","volume":"74","author":"Schiffman","year":"2002","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ijc.2910610407","article-title":"CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy","volume":"61","author":"Yacyshyn","year":"1995","journal-title":"International Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD007287.pub3-BIB0111|cit111","first-page":"4902","article-title":"Immunization with a peptide epitope (p369-377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors","volume":"58","author":"Zaks","year":"1998","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0112|cit112","unstructured":"University of Washington Her-2\/Neu vaccine plus GM-CSF in treating patients with stage III or stage IV breast, ovarian, or non-small cell lung cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0113|cit113","unstructured":"Duke University Biological therapy in treating patients with metastatic cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0114|cit114","unstructured":"Memorial Sloan - Kettering Cancer Center Vaccine therapy in treating patients with ovarian, fallopian tube, or peritoneal cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0115|cit115","unstructured":"National Cancer Institute (NCI) An open label pilot study to evaluate the safety and tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in combination with sargramostim in adults with metastatic carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0116|cit116","unstructured":"University of Virginia Cancer Center and National Cancer Institute (NCI) Evaluation of the immunogenicity of vaccination with synthetic peptides in adjuvant in patients with advanced ovarian, primary peritoneal, or fallopian tube cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0117|cit117","unstructured":"Eisai Medical Research Inc A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0118|cit118","unstructured":"Roswell Park Cancer Institute and National Cancer Institute (NCI) Phase I study of ALVAC(2)-NY-ESO-1(M)\/TRICOM in patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express NY-ESO-1 or LAGE-1 antigen clinicaltrilas.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0119|cit119","unstructured":"Gynecologic Oncology Group and National Cancer Institute (NCI) A phase III randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933) + OPT-821 Versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0120|cit120","unstructured":"National Cancer Institute (NCI) Open label phase I study to evaluate the safety and tolerability of vaccine (GI-6207) consisting of whole, heat-killed recombinant saccharomyces cerevisiae genetically modified to express CEA protein in adults with metastatic CEA-expressing carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0121|cit121","unstructured":"Roswell Park Cancer Institute and National Cancer Institute (NCI) A phase I clinical trial of NY-ESO-1 protein immunization in combination with 5-AZA-2'-deoxycytidine (decitabine) in patients receiving liposomal doxorubicin for recurrent epithelial ovarian or primary peritoneal carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0122|cit122","unstructured":"Celidex Therapeutics A study of CDx-1401 in patients with malignancies known to express NY-ESO-1 clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0123|cit123","unstructured":"Memorial Sloan - Kettering Cancer Center Polyvalent vaccine-KLH conjugate + Opt-821 given in combination with bevacuzimab clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0124|cit124","unstructured":"Memorial Sloan - Kettering Cancer Center Unimolecular pentavalent (Globo-H-GM2-sTN-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0125|cit125","unstructured":"University of Washington Vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0126|cit126","unstructured":"Oslo University Hospital Trial of vaccine therapy in recurrent platinum sensitive ovarian cancer patients clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0127|cit127","unstructured":"Pravin Kaumaya Vaccine therapy in treating patients with metastatic solid tumors clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0128|cit128","unstructured":"Roswell Park Cancer Institute Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0129|cit129","unstructured":"Roswell Park Cancer Institute Sirolimus and vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0130|cit130","unstructured":"COL George Peoples Phase Ib trial of folate binding protein vaccine in ovarian cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0131|cit131","unstructured":"Instituto de Investigacao em Imunologia Clinical trial of a therapeutic vaccine with NY-ESO-1 in combination with the adjuvant monophosphoryl lipid A (MPLA) clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0132|cit132","unstructured":"Mayo Clinic Cyclophosphamide and vaccine therapy in treating patients with stage II-III breast, ovarian, primary peritoneal, or fallopian tube cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0133|cit133","unstructured":"Quest PharmaTech Inc A controlled study of the effectiveness of oregovomab (antibody) plus chemotherapy in advanced ovarian cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0134|cit134","unstructured":"Sunovion Clinical study of WT2725 in patients with advanced solid malignancies clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0135|cit135","unstructured":"Leiden University Medical Center Chemo-immunotherapy (gemcitabine, interferon-alpha 2b and p53 SLP) in patients with platinum-resistant ovarian cancer (CHIP) clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0136|cit136","unstructured":"Roswell Park Cancer Institute Decitabine, vaccine therapy, and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer clinicaltrials.gov"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ejso.2006.03.041","article-title":"Novel therapeutic agents in ovarian cancer","volume":"32","author":"Agarwal","year":"2006","journal-title":"European Journal of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0140|cit140","unstructured":"Brighton Collaboration www.brightoncollaboration.org"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-007-0378-0","article-title":"The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays","volume":"57","author":"Britten","year":"2008","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0142|cit142","unstructured":"Common Terminology Criteria for Adverse Events v4.03 National Institutes of Health, US Department of Health and Human Services2009publication # 09-7473"},{"issue":"27","key":"10.1002\/14651858.CD007287.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/15B66DQMFYYM78CJ","article-title":"NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma","volume":"125","author":"Dong","year":"2006","journal-title":"American Journal of Clinical Pathology"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1455-63","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/1750743X.1.2.163","article-title":"Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease","volume":"1","author":"Leffers","year":"2009","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub3-BIB0148|cit148","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdi112","article-title":"Tumour-infiltrating gamma\/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma","volume":"16","author":"Raspollini","year":"2005","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"51","key":"10.1002\/14651858.CD007287.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD007287.pub3-BIB0153|cit153","first-page":"11","article-title":"Chemotherapy for advanced ovarian cancer: overview of randomized trials","volume":"27","author":"Thigpen","year":"2000","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1002\/14651858.CD007287.pub3-BIB0155|cit155","volume-title":"Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization","year":"1979"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub3-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007287.pub2","article-title":"Antigen-specific active immunotherapy for ovarian cancer","author":"Leffers","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007287.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007287.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T16:27:52Z","timestamp":1717345672000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007287.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":157,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007287.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007287.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,17]]}}}